Treatment of autoimmune hemolytic anemia: real world data from a reference center in Mexico.

Conclusion: Outcomes of w-AIHA treatment were considerably heterogeneous. Low rituximab doses plus high dexamethasone doses were effective for refractory disease. PMID: 31309092 [PubMed]
Source: Blood Research - Category: Hematology Tags: Blood Res Source Type: research